the UKPDS risk engine was developed from a cohort that started including patients in 1977 [8]. Treatment of type 2 diabetes and prevention of CVD has improved since 1977 and the risk of developing CVD has declined with better treatment of type 2 diabetes [22]. Also, as diabetes is now detected at an earlier stage, therapeutic intervention can be initiated earlier, reducing CVD risk even further. Altogether, this is likely to explain the large differences in predicted and observed absolute risks that have led to poor calibration.